We are developing novel drug delivery systems to effectively deliver nucleic acids therapeutics in a clinical setting. One focus of our company is to implement RNA interference (RNAi) via delivery of short interfering RNA. Our initial therapeutic focus is blood cancers, while recognizing that the RNAi activity can be implemented in a large range of human disorders. Another focus is direct administration of plasmid DNA (pDNA) to express proteins in situ. The R&D activity is at preclinical stage and we are committed to undertake the initial development of our therapeutic agents in select human disorders. For disorders beyond the focus of RJH, we are actively looking for pharmaceutical companies to partner with in specific clinical indications. We are ready to delivery systems for a range of nucleic acids in different disease models.
Patient Data :
Gul-Uludag et al. Nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia blasts. Leukemia Research (2014) 38: 1299–1308.
Landry et al. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. J. Controlled Release (2016) 224: 8-21.